Drug Profile
Dornase alfa - Genentech
Alternative Names: DNase; Dornase alpha; dornase-alpha; Pulmozyme; Recombinant human deoxyribonuclease I; rhDNaseLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech; University of Illinois at Chicago
- Class Antifibrotics; Enzymes; Eye disorder therapies; Recombinant proteins
- Mechanism of Action Deoxyribonuclease 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cystic fibrosis
- Phase I/II Dry eyes; Graft-versus-host disease
- Discontinued Chronic obstructive pulmonary disease; COVID 2019 infections; Lupus nephritis
Most Recent Events
- 10 Jan 2022 Discontinued - Phase-II for COVID-2019 infections (Combination therapy) in USA (Inhalation) as per Data Monitoring Committee recommendation
- 10 Jan 2022 Efficacy and safety data from phase II I-SPY COVID trial in COVID-2019 infections released by Quantum Leap Healthcare
- 08 Apr 2021 Dornase alfa is still in phase I/II trials for Graft-Vs-Host Disease in USA (Ophthalmic, drops) (NCT02702518)